{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-237900","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2022-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.603586+00:00","generated_at":"2026-06-23T16:37:01.826119+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silverback terminates President/CSO and CFO; appoints interim CFO ahead of merger","bullets":["Terminated Valerie Odegard (President/CSO) and Jonathan Piazza (CFO), effective Sept 2, 2022, to extend cash runway.","Odegard and Piazza entered consulting agreements at $350/hour (max 20 hrs/wk) through merger close or Nov 30, 2022.","Equity awards continue vesting during consulting period; options remain exercisable.","Russ Hawkinson appointed Interim CFO; he also serves as SVP Finance and principal accounting officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-237900","json":"https://secwatch.observer/filing/0001193125-22-237900.json","markdown":"https://secwatch.observer/filing/0001193125-22-237900.md","text":"https://secwatch.observer/filing/0001193125-22-237900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/0001193125-22-237900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/d352338d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T16:37:01.826119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04579b46fe","claim":"Valerie Odegard was terminated as President and Chief Scientific Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. (“Silverback”) approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/0001193125-22-237900-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"0e713ab2e8","claim":"Russ Hawkinson was appointed as Interim Chief Financial Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Effective as of the Transition Date, Russ Hawkinson has been appointed to serve as Silverback’s Interim Chief Financial Officer and principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/0001193125-22-237900-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"1f02e31b57","claim":"Jonathan Piazza was terminated as Chief Financial Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. (“Silverback”) approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/0001193125-22-237900-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}